RSS-Feed abonnieren
DOI: 10.1055/s-0029-1220231
© Georg Thieme Verlag KG Stuttgart · New York
Prävention von Infektionen und Thrombosen nach Splenektomie oder bei Funktionsverlust der Milz
Prevention of infections and other complications after splenectomyPublikationsverlauf
eingereicht: 27.11.2008
akzeptiert: 12.2.2009
Publikationsdatum:
31. März 2009 (online)

Zusammenfassung
Infektionen, insbesondere durch Kapsel-tragende Bakterien wie Pneumokokken, stellen für Patienten nach Splenektomie eine ernste und potentiell lebensbedrohliche Komplikation dar. Sie wird in internationalen Veröffentlichungen als „post-Splenektomie Sepsis” (PSS) oder „overwhelming postsplenectomy infection” (OPSI) bezeichnet. Zu den Indikationen für eine Splenektomie zählen die traumatische Milzruptur und diverse hämatologische Erkrankungen. Als Erreger bei PSS finden sich am häufigsten Pneumokokken, seltener Haemophilus influenzae, Meningokokken und verschiedene andere Infektionserreger. Es existieren mehrere Strategien, um schweren Infekten nach Splenektomie und ebenso bei Funktionsverlust der Milz vorzubeugen: hierzu zählen Impfungen, die prophylaktische Antibiotikagabe (bei Kindern und Jugendlichen immer in den ersten 3 Jahren nach Splenektomie!), sofortige Antibiotikatherapie bei Infektionsverdacht, umfassende Aufklärung der betroffenen Patienten über die Risiken nach Splenektomie und ein als Dokument getragenes Patientenmerkblatt (bzw. -karte), das über die Splenektomie informiert. Wenn diese Maßnahmen berücksichtigt werden, ist das PSS-Risiko deutlich zu senken.
Summary
Overwhelming Post-Splenectomy Infection (OPSI or PSS), most frequently caused by encapsulated Gram-positive pathogens, is a complication after splenectomy. Reasons for splenectomy include trauma, or malignant and non-malignant hematologic diseases. OPSI-inducing bacteria are mainly Streptococcus pneumoniae and less frequently Haemophilus influenzae, Neisseria meningitides and Gram-negative bacilli. There exist very efficient – albeit often neglected – strategies, how to prevent infections in patients after splenectomy. These include vaccination, prophylactic antibiotics (always for 3 years during childhood and adolescence) and prompt antibiotic treatment, if an infection is suspected. Patients need to know the nature and likelihood of PSS and they should seek immediate medical attention if they become ill or febrile. Each patient should carry at all times a letter or card documenting the splenectomy. With these measures and precautions, the PSS-risk can be significantly reduced or at best be completely avoided.
Schlüsselwörter
Splenektomie - Infektionen - Impfung - Antibiotikaprophylaxe
Keywords
splenectomy - infections - vaccination - antibiotic prophylaxis
Literatur
- 1
Agre P, Asimos A, Casella J F, McMillan C.
Inheritance pattern
and clinical response to splenectomy as a reflection of erythrocyte
spectrin deficiency in hereditary spherocytosis.
N Engl
J Med.
1986;
315
1579-1583
MissingFormLabel
- 2
Balmer P, Falconer M, McDonald P. et al .
Immune response to meningococcal serogroup
C conjugate vaccine in asplenic individuals.
Infect Immun.
2004;
72
332-337
MissingFormLabel
- 3
Bisharat N, Omari H, Lavi I, Raz R.
Risk of infection and death
among post-splenectomy patients.
J Infect.
2001;
43
182-186
MissingFormLabel
- 4
Bolton-Maggs P H, Stevens R F, Dodd N J, Lamont G, Tittensor P, King M J.
General
Haematology Task Force of the British Committee for Standards in
Haematology. Guidelines for the diagnosis and management of hereditary
spherocytosis.
Br J Haematol.
2004;
126
455-474
MissingFormLabel
- 5
Cherif H, Landgren O, Konradsen H B, Kalin M, Bjorkholm M.
Poor antibody response to pneumococcal polysaccharide vaccination
suggests increased susceptibility to pneumococcalinfection in splenectomized
patients with haematological diseases.
Vaccine.
2006;
24
75-81
MissingFormLabel
- 6
Corbett S M, Rebuck J A, Rogers F B. et al .
Time lapse and comorbidities influence
patient knowledge and pursuit of medical care after traumatic splenectomy.
J Trauma.
2007;
62
397-403
MissingFormLabel
- 7
Cullingford G L, Watkins D N, Watts A D, Mallon D F.
Severe
late postsplenectomy infection.
Br J Surg.
1991;
78
716-721
MissingFormLabel
- 8 Cumbria & Lancashire
Health Protection Unit NHS Splenectomy Guidelines June 2002: Guidance
on the Prevention of Infections in Asplenic Patients or Patients
with a Dysfunctional Spleen. http://www.healthprotection.org.uk/.
MissingFormLabel
- 9 Dickerhoff R, Mahlberg R. Sichelzellkrankheiten
Leitlinie der DGHO: Sichelzellkrankheit. April 2005
MissingFormLabel
- 10 Diem H, Heimpel H, Thomalla J. Leitlinie der DGHO: Anämie Anämien. November 2007
MissingFormLabel
- 11
Eber S W, Langendörfer C M, Ditzig M. et al .
Frequency of very late fatal sepsis
after splenectomy for hereditary spherocytosis: impact of insufficient
antibody response to pneumococcal infection.
Ann Hematol.
1999;
78
524-528
MissingFormLabel
- 12
Ejstrud P, Kristensen B, Hansen J B, Madsen K M, Schonheyder H C, Sorensen H T.
Risk and patterns of bacteraemia after splenectomy: a population-based
study.
Scand J Infect Dis.
2000;
32
521-525
MissingFormLabel
- 13
Evans D I.
Postsplenectomy sepsis 10 years or more after operation.
J Clin
Pathol.
1985;
38
309-311
MissingFormLabel
- 14
George J N, Woolf S H, Raskob G E. et al .
Idiopathic thrombocytopenic purpura:
a practice guideline developed by explicit methods for the American
Society of Hematology.
Blood.
1996;
88
3-40
MissingFormLabel
- 15
Hansen K, Singer D B.
Asplenic-hyposplenic
overwhelming sepsis: postsplenectomy sepsis revisited.
Pediatr
Dev Pathol.
2001;
4
105-121
MissingFormLabel
- 16
Heiniger U.
Prävention schwerer Infektionen bei anatomischer oder funktioneller
Asplenie.
BAG-Builletin.
2006;
49
977-983
, www.bag.admin.ch/dokumentation/publikationen
MissingFormLabel
- 17
Holdsworth R, Irving A D, Cuschieri A.
Postsplenectomy sepsis and its mortality rate: actual versus
perceived risks.
Br J Surg.
1991;
78
1031-1038
MissingFormLabel
- 18
Kotsanas D, Al-Souffi M H, Waxman B P, King R W, Polkinghorne K R, Woolley I J.
Adherence to guidelines for prevention of postsplenectomy sepsis.
Age and sex are risk factors: a five-year retrospective review.
ANZ J Surg.
2006;
76
542-547
MissingFormLabel
- 19
Kruetzmann S, Rosado M M, Weber H. et al .
Human immunoglobulin M memory B cells controlling
Streptococcus pneumoniae infections are generated in the spleen.
J Exp Med.
2003;
197
939-945
MissingFormLabel
- 20
Kyaw M H, Holmes E M, Toolis F. et al .
Evaluation of severe infection and survival
after splenectomy.
Am J Med.
2006;
110
276e1-276e7
MissingFormLabel
- 21
Kyaw M, Lynfield H R, Schaffner E. et al .
Effect of introduction of the pneumococcal
conjugate vaccine on drug-resistant Streptococcus pneumoniae.
N Engl J Med.
2006;
354
1455-1463
MissingFormLabel
- 22
Mamani-Matsuda M, Cosma A, Weller S. et al .
The human spleen is a major reservoir for
long-lived vaccinia virus-specific memory B cells.
Blood.
2008;
111
4653-4659
MissingFormLabel
- 23
McVernon J, Howard A J, Slack M P, Ramsay M E.
Long-term
impact of vaccination on Haemophilus influenzae type b (Hib) carriage
in the United Kingdom.
Epidemiol Infect.
2004;
132
765-767
MissingFormLabel
- 24
McVernon J, Trotter C L, Slack M P, Ramsay M E.
Trends
in Haemophilus influenzae type b infections in adults in England
and Wales: surveillance study.
BMJ.
2004;
329
655-658
MissingFormLabel
- 25
Molrine D C, Antin J H, Guinan E C. et al .
Donor immunization with pneumococcal
conjugate vaccine and early protective antibody responses following
allogeneic hematopoietic cell transplantation.
Blood.
2003;
101
831-836
MissingFormLabel
- 26
Molrine D C, Guinan E C, Antin J H. et al .
Donor immunization with
Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone
marrow transplantation.
Blood.
1996;
87
3012-3018
MissingFormLabel
- 27
Musher D M, Ceasar H, Kojic E M. et al .
Administration of protein-conjugate pneumococcal
vaccine to patients who have invasive disease after splenectomy
despite their having received 23-valent pneumococcal polysaccharide
vaccine.
J Infect Dis.
2005;
191
1063-1067
MissingFormLabel
- 28
Musher D M, Rueda A M, Nahm M H, Graviss E A, Rodriguez-Barradas M C.
Initial and subsequent response
to pneumococcal polysaccharide and protein-conjugate vaccines administered
sequentially to adults who have recovered from pneumococcal pneumonia.
J Infect Dis.
2008;
198
1019-1027
MissingFormLabel
- 29
Pietrabissa A, Moretto C, Antonelli G, Morelli L, Marciano E, Mosca F.
Thrombosis in the portal
venous system after elective laparoscopic splenectomy.
Surg
Endosc.
2004;
18
1140-1143
MissingFormLabel
- 30
Pirofski L A, Casadevall A.
Use of licensed vaccines
for active immunization of the immunocompromised host.
Clin
Microbiol Rev.
1998;
11
1-26
MissingFormLabel
- 31 Riddington C, Owusu-Ofori S. Prophylactic antibiotics
for preventing pneumococcal infection in children with sickle cell
disease. Cochrane Database Syst Rev 2002 CD003427
MissingFormLabel
- 32
Robbins J B, Schneerson R.
Evaluating the Haemophilus
influenzae type b conjugate vaccine PRP-D.
N Engl J Med.
1990;
323
1415-1416
MissingFormLabel
- 33
Rutherford E J, Livengood J, Higginbotham M. et al .
Efficacy and safety of pneumococcal revaccination
after splenectomy for trauma.
J Trauma.
1995;
39
448-452
MissingFormLabel
- 34
Seymour J F, Cusack J D, Lerner S A, Pollock R E, Keating M J.
Case/control study of
the role of splenectomy in chronic lymphocytic leukemia.
J Clin
Oncol.
1997;
15
52-60
MissingFormLabel
- 35
Shatz D V, Schinsky M F, Pais L B, Romero-Steiner S, Kirton O C, Carlone G M.
Immune responses of splenectomized trauma patients to the 23-valent
pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days
after splenectomy.
J Trauma.
1998;
44
760-765
MissingFormLabel
- 36
Shatz D V.
Vaccination considerations in the asplenic patient.
Expert Rev
Vaccines.
2005;
4
27-34
MissingFormLabel
- 37
Stamou K M, Toutouzas K G, Kekis P B. et al .
Prospective study of the
incidence and risk factors of postsplenectomy thrombosis of the
portal, mesenteric, and splenic veins.
Arch Surg.
2006;
141
663-669
MissingFormLabel
- 38
Stoehr G A, Rose M A, Eber S W, Heidemann K, Schubert R, Zielen S.
Immunogenicity
of sequential pneumococcal vaccination in subjects splenectomised
for hereditary spherocytosis.
Br J Haematol.
2006;
132
788-790
MissingFormLabel
- 39
Stoehr G A, Sobh J N, Luecken J. et al .
Near-total splenectomy for hereditary spherocytosis:
clinical prospects in relation to disease severity.
Br
J Haematol.
2006;
132
791-793
MissingFormLabel
- 40
Sumaraju V, Smith L G, Smith S M.
Infectious complications in asplenic hosts.
Infect Dis Clin North Am.
2001;
15
551-565
MissingFormLabel
- 41
Soyer T.
Portal vein thrombosis after splenectomy in pediatric hematologic
disease: risk factors, clinical features, and outcome.
J
Pediatr Surg.
2006;
41
1899-902
MissingFormLabel
- 42 Weiss M, Bartmann P, Belohradsky B H, Eber S W, Schulte-Wissermann H.
Infektionsprophylaxe bei Asplenie. In: Scholz H, Belohradsky BH, Heininger U, Kreth W, Roos R Handbuch: Infektionen bei Kindern u. Jugendlichen. (Mit Modifikationen). 5. Aufl. Dtsch Ges pädiatr Infektiol (Futuramed im Druck)MissingFormLabel
Prof. Dr. Monika Engelhardt
Medizinische Universitätsklinik, Abteilung
Innere Medizin I, Hämatologie und Onkologie
Hugstetterstr. 55
79106 Freiburg
Telefon: 0761/270-3246
Fax: 0761/270-3318
eMail: monika.engelhardt@uniklinik-freiburg.de